• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell biology international. >Circular RNA hsa_circ_0085131 is involved in cisplatin-resistance of non-small-cell lung cancer cells by regulating autophagy
【24h】

Circular RNA hsa_circ_0085131 is involved in cisplatin-resistance of non-small-cell lung cancer cells by regulating autophagy

机译：圆形RNA HSA_CIRC_0085131通过调节自噬涉及非小细胞肺癌细胞的顺铂抵抗力

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-small-cell lung carcinoma (NSCLC) continues to top the list of cancer mortalities worldwide. The role of circular RNAs (circRNAs) in tumorigenesis has been increasingly appreciated, although it is relatively unexplored in NSCLC. Herein, we reported the role of hsa_circ_0085131 in NSCLC. In the present study, NSCLC tumor specimens exhibited a higher hsa_circ_0085131 level in comparison to para-tumor samples. And the higher level of hsa_circ_0085131 was associated with recurrence and poorer survival of NSCLC. Moreover, hsa_circ_0085131 promoted cell proliferation and cisplatin (DDP)-resistance. Furthermore, hsa_circ_0085131 regulated cell DDP-resistance by modulating autophagy. Hsa_circ_0085131 acted as a competing endogenous RNA of miR-654-5p to release autophagy-associated factor ATG7 expression, thereby promoting cell chemoresistance. In conclusion, hsa_circ_0085131 enhances DDP-resistance of NSCLC cells through sequestering miR-654-5p to upregulate ATG7, leading to cell autophagy. Therefore, these findings advocate targeting the hsa_circ_0085131/miR-654-5p/ATG7 axis as a potential therapeutic option for patients with NSCLC who are resistant to DDP.
机译：非小细胞肺癌（NSCLC）继续位居全球癌症死亡率之首。循环RNA（CircRNA）在肿瘤发生中的作用越来越受到重视，尽管它在非小细胞肺癌中的研究相对较少。在此，我们报告了hsa_circ_0085131在非小细胞肺癌中的作用。在本研究中，与肿瘤旁样本相比，NSCLC肿瘤样本显示出更高的hsa_circ_0085131水平。hsa_circ_0085131的高水平与NSCLC的复发和较差的生存率相关。此外，hsa_circ_0085131促进了细胞增殖和顺铂（DDP）耐药性。此外，hsa_circ_0085131通过调节自噬调节细胞DDP抵抗。Hsa_circ_0085131作为miR-654-5p的竞争性内源性RNA，释放自噬相关因子ATG7表达，从而促进细胞的化疗耐药性。总之，hsa_circ_0085131通过隔离miR-654-5p上调ATG7，导致细胞自噬，从而增强NSCLC细胞对DDP的耐药性。因此，这些发现主张针对hsa_circ_0085131/miR-654-5p/ATG7轴，作为对DDP耐药的NSCLC患者的潜在治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号